Trial Profile
A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary) ; Corticosteroids; Prednisolone acetate
- Indications Anterior uveitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 05 Nov 2020 According to an Aldeyra Therapeutics media release, the peer-reviewed Journal of Ocular Pharmacology and Therapeutics published the positive results of a randomized, corticosteroid-controlled Phase 2 clinical trial of reproxalap in patients with noninfectious anterior uveitis
- 25 Oct 2017 According to an Aldeyra Therapeutics media release, data from this trial will presented at the American Uveitis Society Fall Meeting held in conjunction with the American Academy of Ophthalmology 2017 Annual Meeting.
- 17 May 2017 According to an Aldeyra Therapeutics media release, data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting.